Eli Lilly has agreed to buy biopharmaceutical company Morphic Holding for $3.2 billion in a deal that bolsters the drugmaker’s immunology pipeline.
Related Posts
TotalEnergies Expects Flat Hydrocarbon Output
TotalEnergies said it expected third-quarter hydrocarbon production to remain largely unchanged from the second quarter, as it reported a fall in net profit for the […]
Volkswagen Slashes Guidance as Challenges Pile Up
Volkswagen cut its sales and profitability forecasts for the year, joining a growing list of European rivals in lowering their targets as the industry faces […]
Top Jeep Dealers Blame CEO for ‘Disastrous Choices’
A sharply worded letter from a dealer advisory group to Stellantis Chief Executive Carlos Tavares urged action on sagging sales.